Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 3 Nov 2026
Promising but preliminary

Measurable Residual Disease in IDH-Mutated AML: Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring.

A blood test measuring IDH mutations may help predict outcomes in certain leukemia patients, guiding treatment monitoring decisions.

METHODS, We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single-center cohort of patients with IDH-mutated AML treated with curative intent. CONCLUSIONS, A 0,2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH-based MRD assessment in AML.

What the study was

Study design
Prospective biomarker cohort / analytical validation
Population
patients
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
European journal of haematology

Why it surfaced

Abstract-reviewed prospective biomarker cohort / analytical validation scored conservatively for genomics/precision medicine; 8/10 reflects the available design, relevance, novelty, and population or unmet-need evidence.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.